Error: Contact form not found.
Please see below articles on where we have been featuring world wide. Be sure to visit our social pages for more updates.
MmRNA Scientific Colloquium on vaccine access and equity on the African Continent
On Monday 27 November in Capetown, South Africa at #Afrigen, the 3rd Scientific Colloquium dived into the current thinking and how scientific innovation in the field of #mrnavaccines will lead to game changing access in the next few years on the African continent. With the mRNA…
Click on this link to view
There will be a dedicated day focused on RNA Technology at Biomolecular Horizons 2024 Horizons. CEO of Afrigen Biologics, Dr. Petro Terblanche will be a main speaker! Join us at #BMH2024 in Melbourne 22-26 Sept 2024 #Africa 🌍 #Medicine #Science #LMICs #afrigen #afrigenbiologics
Leann Tilley The IUBMB Ilona Irina Concha-Grabinger Terry Piva Sheila Nathan Erinna Lee Sharad Kumar AM FAA FAHMS Andy Hill Johnson Mak Juan Carlos Slebe Tajmuch Melissa Pitman James Murphy, Wayne Patrick, The Australian Society for Microbiology, American Society for Biochemistry and Molecular Biology (ASBMB), #FAOBMB, #COMBIO, The Australian Society for Microbiology, Yerandy Hechavarria
8 Park Joon-eon I 0 Approved 2023.10.12 17:57
to the treatment of both blood cancer and solid cancer, and promoted commercialization with South African companies
A company in Gimhae has developed a cell therapy product (GT516. anti DR4 CAR-TI that can be applied to ‘solid tumors’ beyond the existing cell therapy (CD19 CAR-T), which was applied only to blood cancer. In particular, this treatment can remove cancer cells in a double way, and if it succeeds in clinical trials, it is expected to make a breakthrough in cancer treatment in the future. CAR-T therapy is a new concept of anticancer drug that combines immune ‘T cells’ and ‘gene manipulation’ technologies. Gimhae Biomedical & Industry Promotion Agency announced on the 12th that Geneuintech Co.,Ltd. signed a MOU with South Africa’s ‘Afrigen Biologics & Vaccines’ in September related to CAR-T technology for anti-cancer cell therapy. The main content of the agreement is to jointly carry out and commercialize the technologies and procedures necessary for the launch of new drugs, such as clinical trials for human subjects of therapeutics developed by Geneuintech Co.,Ltd. The treatment can be launched as soon as it passes a “phase 2 clinical trial” to test its “efficacy.”
Existing cell therapies have already been developed and marketed by many global pharmaceutical companies, but they are limited to blood cancer and are expensive enough to apply. However, the new cell therapy product developed by Geneuintech Co.,Ltd. uses genes involved in the death of existing cancer cells, and can strongly remove cancer cells by sending cancer cell suicide signals at the same time as cancer cell death with CAR-T cells. In particular, it can be applied to the treatment of blood cancers such as leukemia, as well as the treatment of solid cancers such as liver cancer and lung cancer. This technology has even been patented in the United States and Europe. Geneuintech Co.,Ltd. was founded as a start-up company in 2015 at lnje University College of Pharmacy. In 2021, Afrigen was selected as the host of the mRNA Technology Transfer Hub (Consortium) program. A type of vaccine developed by Afrigen using genetic information transfer proteins. It also plays a key role in global projects to supply mRNA vaccines to low- and middle-income countries in Africa. Currently, Afrigen is accelerating the preparation of production facilities for the commercialization of CAR-T technology of Geneuintech Co.,Ltd. Park Joon-un
Copyright holder© Gyeongnam llbo – Korea’s first local newspaper prohibited from unauthorized reprinting and redistribution
Click here to read more ⬇
University of Wisconsin-Madison graduate student Elizabeth Appelt laid the foundation that led UW leaders Brian Fox, chair of the University of Wisconsin–Madison Department of Biochemistry, and Jorge Osorio, director of the University of Wisconsin-Madison Global Health Institute, as well as Bill Checovich of Illumina, to join WARF CEO Erik Iverson to explore joint academic and research opportunities in South Africa. They’re pictured here with Linda-Gail Bekker of the UCT Institute of Infectious Disease and Molecular Medicine.
The group met with representatives from Afrigen Biologics (Pty) Ltd, Stellenbosch University and the Desmond Tutu Health Foundation, as well as Nadia Carstens and Craig Kinnear from the South African Medical Research Council (SAMRC) Genomics Centre.
“Phenomenal science and product development are happening everywhere, and the university and WARF have a role to play in that,” says Erik. “If you think WARF can help open a door for you – whether it is your department, your lab or on behalf of your students, please reach out and let us know. We love introducing friends to one another.”
🔹If you’ve ever been awakened in the night or stopped in your tracks by a sudden charley horse, you know that muscle cramps can cause severe pain. Almost everyone has muscle cramps at some time, though generally harmless, muscle cramps can make it temporarily impossible to use the affected muscle.
🔹A muscle cramp is a sudden, brief, involuntary contraction of one or more of your muscles, but what causes it?
🔹 Although the exact cause of muscle cramps is idiopathic the most common are benign leg that occur typically at night and exercise-associated muscle cramping . In fact NLC (Nocturnal leg cramps) are so common that it occurs >5 x per month reported by 6% of the adult US population .
Click here for more information:
Afrigen welcomes enquiries for bulk nanotech orders.
➡ Partnership based on a highly protective #vaccine candidate identified by Evaxion Biotech A/S’s EDENTM platform
➡ The collaboration will access mRNA technology from the World Health Organization and Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub
➡ Afrigen responsible for the development and commercialization of the resulting mRNA vaccine in LMICs and African territories
If we can develop the technology and APIs to manufacture PrEP locally, with other mRNA-based products, SA could position itself at the forefront of this initiative. The world-renowned Afrigen Biologics mRNA hub in Cape Town already aims to contribute to this project by working on the development of new vaccines for diseases that are rampant in lower and middle-income countries.
Afrigen Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalized by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa. It was founded in 2014 by Steven G. Reed (PhD) and Erik Iverson (JD, LLM), both of the Infectious Diseases Research Institute (IDRI) www.idri.org in Seattle. Afrigen drives a business strategy focussing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs. Through international partnerships and local capacity building, Afrigen has established the first ever adjuvant production and formulation technology centre on the African continent. This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value. These adjuvants confer added potency and durability to vaccines. More recently, Afrigen has ventured into the novel CAM’s space where it aims to bring innovative, differentiated products to market.MORE ABOUT US
Specialised equipment commonly used in the formulation industry is housed at our R&D laboratories in Cape Town. Afrigen’s highly trained and experienced scientific staff assist with protocol development, validation and analyses. Accurate, reliable and timeous results performed in accordance with GLP principles are provided. Afrigen offers services to collaborators and outside organisations in two key areas: